Trump nominates Heidi Overton to lead US Food and Drug Administration

President Donald Trump has nominated Heidi Overton, a policy aide, to lead the U.S. Food and Drug Administration (FDA), signaling a potential shift in the agency's direction. Trump announced the nomination on social media, stating that Overton would champion "America First" policies at the regulatory body responsible for drug standards and public health.

Overton, who previously worked at the America First Policy Institute, a think tank aligned with Trump's priorities, is described by the president as a "ROCKSTAR" who has delivered on a "TRANSFORMATIVE Health Agenda." Trump highlighted her ability to tackle difficult issues and find solutions beneficial to the country. Her nomination aims to fill the vacancy left by Dr. Marty Makary, who resigned in May.

The nomination comes amid a complex relationship between the Trump administration and health agencies, where scientific consensus has sometimes clashed with the president's initiatives. Overton's background includes medical school at the University of New Mexico and a doctorate in clinical investigation from Johns Hopkins University. She has also been a vocal critic of abortion pills and has supported Trump's efforts to negotiate drug prices with pharmaceutical companies.

Overton's confirmation now rests with the U.S. Senate. Her potential leadership at the FDA could influence policies on drug approvals, public health initiatives, and regulatory oversight, particularly concerning issues like abortion pills and drug pricing, which have been central to the administration's agenda.

“

Today I am honoured to nominate the wonderful Dr Heidi Overton, MD, PhD, as our next FDA Commissioner. Dr Heidi has been a ROCKSTAR in my Administration, where she has worked directly with [Health and Human Services] Secretary Kennedy, Dr Oz, and team, to deliver on the MOST TRANSFORMATIVE Health Agenda in History. She is known to take on the HARDEST issues, and bring me solutions that work best for the Country.